However, given the risk of increased cardiac burden due to fluid retention and edema, which are typical adverse events of anti-VEGF and anti-VEGF receptor inhibitors, caution should be exercised when administering these drugs to NSCLC patients with severe to most severe COPD. This evidence concerns the gene VEGFA and chronic obstructive pulmonary disease.